


STATIN

NEWSLETTER



A CURATED WEEKLY OVERVIEW OF ALL STATIN PUBLICATIONS

Update week 01 & 02 - 2022

Dr. Peter Lansberg is a Dutch lipidologist, educator and innovator. He has been instrumental in setting up The Dutch National Lipid Clinic Network, the Dutch Lipid Clinic Criteria for Familial Hypercholesterolemia (FH), and the Dutch National FH screening program

The Statin Newsletter will keep you up-to-date with all recent statin publications. Based on a curated approach to select relevant articles.

For live updates you can follow me on twitter

Key Publications

1. **Can HbA1C predict NODM after statins initiation**
2. **Improving secondary prevention medication by simple audit**
3. **Statins and AKI in PAD patients - promising outcomes**
4. **Starting the right medication and right dosage after hospital discharge**
5. **Simple tool to estimate sd-LDL: TG/LDL-c ratio**

Paradoxical relationship between HbA1c and statins triggered NODM

For this retrospective analysis, to determine if baseline HbA1C is an independent risk factor for statin-induced new-onset diabetes mellitus (NODM), data collected in the Veterans Healthcare Administration was queried. Between January 2011 and December 2018, 152 358 patients were included and followed for an average period of 6.89 (SD 2.26) years. In non-statin users and 3.85 (SD 2.29) in statin users. Baseline HbA1c values were stratified into three categories: $\leq 5.6\%$, 5.7%–5.9%, and 6.0%–6.4%. The incidence of statin-induced NODM was 224.5 extra cases per 100 000 patients over a 4-year follow-up. This largest to date analysis of the diabetogenic risk of statins vs. patients not using statins, closely matched for baseline characteristics, showed an unexpected reverse association between HbA1C and NODM. Overall, the statin users HRs were 2.08 (1.85-2.35), 1.57 (1.40-1.75) and 1.03 (0.93-1.15) for HbA1c groups of $\leq 5.6\%$, 5.7%–5.9% and 6.0%–6.4%, respectively ($p < 0.0001$). There was no significant difference in diabetogenic risk among different statin groups. The hypothesis for this finding is that an HbA1C between 6.0% and 6.4% is by itself associated with an increased risk of NODM, eradicating additional risk posed by statins. The authors recommended that the A1c value at the time of a patient-provider shared decision-making session should be included to discuss diabetogenic risks of statin therapy.

Ziganshina AP, Gemoets DE, Kaminsky LS, Gosmanov AR. **Baseline hemoglobin A1c and risk of statin-induced diabetes: results of Veterans Affairs Database analysis.** BMJ open diabetes research & care 2022; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34987054>

Improving management of post-ACS patients by a simple audit strategy

Retrospective studies on medical management of post ACS patients have repeatedly shown the gap between guideline recommend medication and dosages and real-world implementation of these recommendations. In this pharmacist-based intervention, discharge prescriptions were audited by hospital pharmacists. The medications monitored were statins, dual antiplatelet therapy (DAPT), beta-blockers, and angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin receptor blockers (ARB). Every month, a feedback report was presented to the cardiologist managing the discharged patients. The trends in the adherence to guideline-recommended medication were analyzed over 12 months. A total of 1072 patients participated in this prospective study. In the first month, omissions of DAPT, statin, ACE-I/ARB, and beta-blockers were observed in 1%, 0%, 14%, and 11%, respectively, which reduced to nil by the end of the 11th month of the audit. This remained unchanged until the end of the 12th month. The observed findings illustrate how a simple and effective strategy ensures that guideline-recommended medications are appropriately prescribed in post- ACS patients. The simple strategy can be easily implemented in both developed economies as in countries and hospitals with limited resources.

George NE, Shukkoor AA, Joseph N *et al.* **Implementation of clinical audit to improve adherence to guideline-recommended therapy in acute coronary syndrome.** The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2022; 74:4. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35020077>

Can statins protect PAD patients from AKI

Patients with symptomatic peripheral artery disease (PAD) are at risk for acute kidney injury (AKI). This is partly due to advanced atherosclerosis and the nephrotoxic contrast medium used for angiographic imaging and interventions. A retrospective analysis of hospitalized PAD patients was conducted to explore the protective effects of statins on the incidence of AKI in patients with PAD. Data collected in the endovascular treatment database of a single hospital was used, and a total of 295 PAD patients that underwent an angiography or intervention were included for this analysis. Patients without statins (N=157) were compared to patients that used statins for at least one month prior to admission (N=138). Patients that used statins were more likely to have DM, were younger, had a higher BMI, and a lower LDL-c. The dose of contrast medium administered, ACEi/ARB's use, smoking habits, and blood pressure were similar. The incidence of AKI was significantly reduced in the statin user compared to the controls, 5% vs. 16% (P<0.05). The findings of this retrospective analysis show that the use of statins were associated with a reduced risk of AKI; due to the observational design of this analysis, a prospective and randomized study is warranted to corroborate these findings.

Kanai D, Fujii H, Nakai K *et al.* **Statin Use Influence on the Occurrence of Acute Kidney Injury in Patients with Peripheral Arterial Disease.** J Atheroscler Thromb 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35013022>

Overcoming prescription inertia in secondary prevention

Medication used by patients admitted for an ACS is frequently continued without adjusting the dosage or adding a guideline-recommended medication that was not used prior to the hospitalization. In this retrospective analysis of a single Hong Kong tertiary referral hospital, discharge medication of secondary prevention therapies (aspirin, beta-blockers, statins, and ACEI/ ARBs) were evaluated for 12-month survival. Prescription rates of aspirin, beta-blocker, statin, and ACEI/ARBs on discharge were 94.8%, 64.5%, 83.5%, and 61.4%, respectively. Prior use of each drug class was an independent predictor of the same class medication at discharge; OR: 4.8 (1.9–12.3, P < 0.01); beta-blocker, OR: 2.5 (1.8–3.4, P < 0.01); statin, OR: 8.3 (0.4–15.7, P < 0.01), and ACEI/ARBs OR: 2.9 (2.0–4.3, P < 0.01). Passive continuation of medication used was associated with an increased 1-year mortality compared to active initiation in treatment naive patients, aspirin (13.7% vs. 5.7%), beta-

blockers (12.9% vs. 5.6%), and statins (11.0% vs. 4.6%); all $P < 0.01$. Overall the use of medication for secondary prevention was suboptimal. The continuation of sub-therapeutic dosages of secondary prevention medication was a common finding in patients discharged after an ASCVD event and warrants strategies to ensure that these very high ASCVD risk patients are adequately managed.

Xurui Huang N, Sanderson JE, Fang F *et al.* **Passive Prescription of Secondary Prevention Medical Therapy during Index Hospitalization for Acute Myocardial Infarction Is Prevalent and Associated with Adverse Clinical Outcomes.** *J Healthc Eng* 2021; 2021:9543912. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34976331>

Estimating sd-LDL; the TG/LDL-c ratio comes very close!

In patients with type 2 diabetes (DM2), LDL-c is not that much higher than non-diabetic patients. The type and pro-atherogenic qualities of LDL particles in diabetics are different and translate into a much higher ASCVD risk. Small dense LDL (sd-LDL) is considered a relevant risk marker in diabetes or metabolic syndrome/ insulin resistance patients. Measuring the plasma concentrations of sdLDL is possible but at increased costs and not always available in many hospitals. This analytical study evaluated the relationship between LDL size – using LDL- migration index (LDL-MI) based on electrophoresis polyacrylamide gel and simple plasma lipid concentrations. A cut-off value of ≥ 0.400 was used to determine increased LDL size. Based on a C-statistics model, different fractions and ratios (TGs, non-HDL-C, TG/LDL-C ratio, TG/HDL-C ratio, and non-HDL-C/HDL-C) were evaluated. The TG/LDL-c ratio reached an AUC of 0.945 (0.884-1.00) in patients not treated with statins. The optimal cut-off point for TG/LDL-C ratio for increased LDL-MI was 1.1 (molar ratio) regardless of statin treatment. The sensitivity and specificity of the TG/LDL-C ratio (90.0 and 93.9%, respectively) were higher than those of non-HDL-C (56.7 and 78.8%, respectively) in patients without statins. The TG/LDL-c ratio may provide a simple clinical tool for predicting increased sd-LDL and could help reduce residual risk in diabetic or insulin-resistant patients.

Ouchi G, Komiya I, Taira S *et al.* **Triglyceride/low-density-lipoprotein cholesterol ratio is the most valuable predictor for increased small, dense LDL in type 2 diabetes patients.** *Lipids Health Dis* 2022; 21:4. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34996463>

Relevant Publications

1. Firnhaber JM, Powell CS. Arterial Atherosclerosis: Vascular Surgery Interventions. *American family physician* 2022; 105:65-72. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35029953>
2. Minhas AMK, Ijaz SH. Disparities in Statin Use During Outpatient Visits of Adults (Age 18 to 64 Years) With Coronary Heart Disease in the Medicaid Population in the United States (from the National Ambulatory Medical Care Survey Database 2006 to 2015). *Am J Cardiol* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974897>
3. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. *Bmj* 2022; 376:e068407. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34996756>
4. Al-Karaghoul M, Fuentes S, Davyduke T *et al.* Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD. *BMJ Open Gastroenterol* 2022; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34992072>
5. Inasu M, Feldt M, Jernström H *et al.* Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study. *Breast* 2022; 61:123-128. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34995921>
6. Berberich AJ. The Power to Predict: Does LDLR Mutation Status Determine Statin Responsiveness? *Can J Cardiol* 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35032620>

7. Michaeli DT, Michaeli JC, Boch T, Michaeli T. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany. Cardiovasc Drugs Ther 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35015186>
8. Lan NSR, Ali US, LARBalestier R *et al.* An opportunity to improve secondary prevention with icosapent ethyl in patients who have undergone coronary artery bypass graft surgery. Cardiovascular revascularization medicine : including molecular interventions 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974987>
9. Voora D, Baye J, McDermaid A *et al.* SLCO1B1*5 Allele is Associated with Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care. Clinical pharmacology and therapeutics 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35034348>
10. Osborn H, Grossman D, Kochhar S *et al.* A Rare Case of Delayed Onset Multi-Drug Interaction Resulting in Rhabdomyolysis in a 66-Year-Old Male. Cureus 2021; 13:e20035. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34987920>
11. Pirillo A, Catapano AL. New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. Current opinion in endocrinology, diabetes, and obesity 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34980867>
12. Giannotti N, McNulty J, Foley S *et al.* Association Between 18-FDG Positron Emission Tomography and MRI Biomarkers of Plaque Vulnerability in Patients With Symptomatic Carotid Stenosis. Frontiers in neurology 2021; 12:731744. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35002912>
13. Locuratolo N, Scicchitano P, Antoncicchi E *et al.* [Follow-up of patients after an acute coronary event: the Apulia PONTE-SCA program]. Giornale italiano di cardiologia (2006) 2022; 23:63-74. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34985464>
14. Grassi G, Del Pinto R, Agabiti Rosei C *et al.* Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34978703>
15. McCaughey C, Ranganathan D, Kerins M *et al.* Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre: analysis of the impact of new ESC guidance on LDL-C target achievement. Irish journal of medical science 2022:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35031936>
16. Singh N, Bhatt DL, Miller M *et al.* Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. J Am Coll Cardiol 2022; 79:220-222. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35027114>
17. Wu WY, Biery DW, Berman AN *et al.* Impact of coronary artery calcium testing on patient management. Journal of cardiovascular computed tomography 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34998708>
18. Arora S, Qamar A, Gupta P *et al.* Guideline based eligibility for primary prevention statin therapy - Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI). J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34996741>
19. Milner E, Ainsworth M, Gleaton M, Bookstaver D. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins. Journal of clinical pharmacy and therapeutics 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35032137>
20. Yu J, Wang AA, Zimmerman LP *et al.* A Cohort Analysis of Statin Treatment Patterns Among Small-Sized Primary Care Practices. Journal of general internal medicine 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34997391>
21. Zhang Y, Flory JH, Bao Y. Chronic Medication Nonadherence and Potentially Preventable Healthcare Utilization and Spending Among Medicare Patients. Journal of general internal medicine 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35018567>
22. Williams PT. Quantile-Specific Heritability of Inflammatory and Oxidative Stress Biomarkers Linked to Cardiovascular Disease. J Inflamm Res 2022; 15:85-103. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35023945>

23. Sridharan ND, Asaadi S, Thirumala PD, Avgerinos ED. A systematic review of cognitive function after carotid endarterectomy in asymptomatic patients. Journal of vascular surgery 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34995717>
24. Sigrist K, Winkler J, Westphalen A, Yuen B. [Citrus paradisi (grapefruit)-a negative interaction with a statin]. Med Klin Intensivmed Notfmed 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34989821>
25. Hunt NB, Emmens JE, Irawati S *et al*. Sex disparities in the effect of statins on lipid parameters: The PharmLines Initiative. Medicine (Baltimore) 2022; 101:e28394. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35029178>
26. Wang L, Zhu L, Zheng Z *et al*. Mevalonate pathway orchestrates insulin signaling via RAB14 geranylgeranylation-mediated phosphorylation of AKT to regulate hepatic glucose metabolism. Metabolism 2022; 128:155120. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34995578>
27. Al-Kuraishy HM, Hussien NR, Al-Naimi MS *et al*. Statins Therapy Improves Acute Ischemic Stroke in Patients with Cardio-metabolic Disorders Measured by Lipoprotein-Associated Phospholipase A2 (Lp-PLA2): New Focal Point. Neurology India 2021; 69:1637-1644. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34979662>
28. Iannuzzo G, Buonaiuto A, Calcaterra I *et al*. Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study. Nutrition, metabolism, and cardiovascular diseases : NMCD 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34991937>
29. Ding C, Li Y, Li X *et al*. QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats. Pharmaceutical biology 2022; 60:185-194. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35001796>
30. Eshtiaghi A, Popovic MM, Sothivannan A *et al*. Statin Use and The Incidence of Age-Related Macular Degeneration: A Meta-Analysis. Retina 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34983903>
31. Coy K, Stys A, Stys T, DeVries J. Proprotein Convertase Subtilism/Kexin 9 (PCSK9) Inhibitors: Adding to the Armamentarium of the Primary Care Physician. South Dakota medicine : the journal of the South Dakota State Medical Association 2021; 74:454-456. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34995425>
32. Masilela C, Adeniyi OV, Benjeddou M. Prevalence, patterns and determinants of dyslipidaemia among South African adults with comorbidities. Scientific reports 2022; 12:337. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35013433>
33. Sarraju A, Ward A, Li J *et al*. Personalizing cholesterol treatment recommendations for primary cardiovascular disease prevention. Scientific reports 2022; 12:23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34996943>
34. Kim H, Kim JK. Evidence on Statins, Omega-3, and Prostate Cancer: A Narrative Review. World J Mens Health 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35021299>
35. Boccara F, Caramelli B, Calmy A *et al*. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period. Aids 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35025817>
36. Ho J, Kim B, Kim KS *et al*. Statin Supply and Polydrug Use in Older Adults: A Focus on Drug Combinations that Reduce Bone Density. Ann Geriatr Med Res 2021; 25:269-277. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34986544>
37. Acheampong T, Lee Argov EJ, Terry MB *et al*. Current regular aspirin use and mammographic breast density: a cross-sectional analysis considering concurrent statin and metformin use. Cancer Causes Control 2022; 33:363-371. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35022893>
38. Larsen SB, Dehlendorff C, Skriver C *et al*. Prescription rates for commonly used drugs before and after a prostate cancer diagnosis. Cancer Causes Control 2022; 33:417-428. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35006514>
39. Goh MJ, Sinn DH. Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further? Clinical and molecular hepatology 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35021597>

40. Al Megalli M, Bashir S, Qadah H *et al.* Colchicine-Induced Acute Myopathy: Case Study From Saudi Arabia. Cureus 2021; 13:e20290. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35028201>
41. Son KB, Lee EK. Importance of a usual source of care in choosing low-priced generic drugs: a cross-sectional study. Family practice 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35022685>
42. Alsehli AM, Rukh G, Clemensson LE *et al.* Differential associations of statin treatment and polymorphism in genes coding for HMGCR and PCSK9 to risk for insomnia. Frontiers in bioscience (Landmark edition) 2021; 26:1453-1463. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34994160>
43. Tu B, Tang Y, Cheng Y *et al.* Association of Prior to Intensive Care Unit Statin Use With Outcomes on Patients With Acute Kidney Injury. Frontiers in medicine 2021; 8:810651. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35004788>
44. Kuno T, So M, Iwagami M *et al.* The association of statins use with survival of patients with COVID-19. J Cardiol 2021; 79:494-500. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34974938>
45. Gupta L, Nune A, Naveen R *et al.* The prevalence and clinical characteristics of anti-HMGCR (anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase) antibodies in idiopathic inflammatory myopathy: an analysis from the MyoCite registry. Rheumatology international 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35031847>
46. Bogari NM, Babalghith AO, Bouazzaoui A *et al.* Assessment of genetic polymorphism associated with ATP-binding cassette transporter A1 (ABCA1) gene and fluctuations in serum lipid profile levels in patients with coronary artery disease. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2021; 29:1458-1465. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35002384>

Basic Science

1. Kornelsen V, Unger M, Kumar A. Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against *Acinetobacter baumannii* ATCC17978 or *A. baumannii* AB030. Access Microbiol 2021; 3:000288. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35018330>
2. Zabihi M, Askarian F, Hekmatimoghaddam S *et al.* Ascorbic Acid Significantly Decreases Creatine Kinase Plasma Levels in an Animal Model of Statin/Fibrate-Induced Myopathy. Adv Pharmacol Pharm Sci 2021; 2021:5539595. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35005624>
3. Chen D, Sui L, Chen C *et al.* Atorvastatin suppresses NLRP3 inflammasome activation in intracerebral hemorrhage via TLR4- and MyD88-dependent pathways. Aging 2022; 14:462-476. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35017318>
4. Sharma A, Sanjeev K, Selvanathan VMJ *et al.* The evaluation of cytotoxicity and cytokine IL-6 production of root canal sealers with and without the incorporation of simvastatin: an invitro study. BMC oral health 2022; 22:6. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35012572>
5. Cao Y, Chen Z, Jia J *et al.* Rosuvastatin Alleviates Coronary Microembolization-Induced Cardiac Injury by Suppressing Nox2-Induced ROS Overproduction and Myocardial Apoptosis. Cardiovasc Toxicol 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34997458>
6. Abolghasemi R, Ebrahimi-Barough S, Mohamadnia A, Ai J. Synergistic inhibitory effect of human umbilical cord matrix mesenchymal stem cells-conditioned medium and atorvastatin on MCF7 cancer cells viability and migration. Cell Tissue Bank 2022:1-23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34988840>

7. Gergen AK, Madsen HJ, Li A *et al.* Simvastatin Inhibits Histologic Changes Associated with Gastroduodenal Reflux in a Murine Model. [Digestive diseases and sciences](http://www.ncbi.nlm.nih.gov/pubmed/?term=35001242) 2022. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35001242>
8. Wijaya A, Wang Y, Tang D *et al.* A study of lovastatin and L-arginine co-loaded PLGA nanomedicine for enhancing nitric oxide production and eNOS expression. [Journal of materials chemistry, B](http://www.ncbi.nlm.nih.gov/pubmed/?term=34994373) 2022; 10:607-624. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34994373>
9. Yu Z, Guo J, Liu Y *et al.* Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. [J Nanobiotechnology](http://www.ncbi.nlm.nih.gov/pubmed/?term=34983554) 2022; 20:9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34983554>
10. Roušarová J, Šíma M, Kozlík P *et al.* Changes in Rosuvastatin Pharmacokinetics During Postnatal Ontogenesis in Rats. [Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques](http://www.ncbi.nlm.nih.gov/pubmed/?term=34995472) 2021; 25:1-8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34995472>
11. Wei J, Huan Y, Heng Z *et al.* Dynamic urine proteome changes in a rat model of simvastatin-induced skeletal muscle injury. [J Proteomics](http://www.ncbi.nlm.nih.gov/pubmed/?term=34990819) 2022; 254:104477. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34990819>
12. Chen Z, Chow TCH, Wang S *et al.* Reaction of the Liver upon Long-Term Treatment of Fluoxetine and Atorvastatin Compared with Alcohol in a Mouse Model. [J Toxicol](http://www.ncbi.nlm.nih.gov/pubmed/?term=35003254) 2021; 2021:9974969. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35003254>
13. Tulbah AS, Gamal A. Design and Characterization of Atorvastatin Dry Powder Formulation as a potential Lung Cancer Treatment. [Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society](http://www.ncbi.nlm.nih.gov/pubmed/?term=35002383) 2021; 29:1449-1457. <http://www.ncbi.nlm.nih.gov/pubmed/?term=35002383>
14. Vemuri VD, Lankalapalli S. Cocrystal Construction Between Rosuvastatin Calcium and L-asparagine with Enhanced Solubility and Dissolution Rate. [Turk J Pharm Sci](http://www.ncbi.nlm.nih.gov/pubmed/?term=34979738) 2021; 18:790-798. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34979738>

To subscribe to the Statin Literature Update Service Click [HERE](#)



Facebook



Twitter



Website

mailing address:
lansberg@gmail.com

© P.J. Lansberg